RL
80
-3
AA
43
2
MCHP
62
11
PFE
23
-5
PM
75
-2
LLY
56
9
CAH
69
2
LEG
55
2
IBM
58
-3
HES
42
2
ILMN
45
-4
CVX
32
3
CNP
46
-14
DHI
25
-2
MO
57
-3
CF
51
-5
MAR
72
-2
MAT
52
-3
AIG
60
3
MCK
73
2
RL
80
-3
AA
43
2
MCHP
62
11
PFE
23
-5
PM
75
-2
LLY
56
9
CAH
69
2
LEG
55
2
IBM
58
-3
HES
42
2
ILMN
45
-4
CVX
32
3
CNP
46
-14
DHI
25
-2
MO
57
-3
CF
51
-5
MAR
72
-2
MAT
52
-3
AIG
60
3
MCK
73
2
Financhill
Back

Sage Therapeutics 10K Form

Sell
23

SAGE
Sage Therapeutics

Last Price:
$6.76
Seasonality Move:
-1.48%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SAGE News And Ratings

See the #1 stock for the next 7 days that we like better than SAGE

SAGE Financial Statistics

Sales & Book Value

Annual Sales: $41.2M
Cash Flow: $-81.7M
Price / Cash Flow: 0
Annual Sales: $6.55
Price / Book: 1

Profitability

EPS (TTM): -5.80000
Net Income (TTM): $-354.4M
Gross Margin: $31.8M
Return on Equity: -64.19%
Return on Assets: -57.09%

Sage Therapeutics Earnings Forecast

Key Sage Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 12 years for SAGE is 77.10%.
  • The Selling, General & Administrative Expenses for SAGE have been equal to 524.74% of Gross Profit Margin.
  • The Research & Development expenses have been 547.72% of Revenue.
  • Per Share Earnings over the last 13 years have been positive in 2 years.

Sage Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SAGE
CUSIP: 78667J
Website: sagerx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 9.13
Quick Ratio: 8.73

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

SAGE Technical Analysis vs Fundamental Analysis

Sell
23
Sage Therapeutics (SAGE) is a Sell

Is Sage Therapeutics a Buy or a Sell?

  • Sage Therapeutics stock is rated a Sell
    The current Sage Therapeutics [SAGE] share price is $6.56. The Score for SAGE is 23, which is 54% below its historic median score of 50, and infers higher risk than normal.